Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020. The report details the vesting of awards under the 2017 Performance Share Plan (PSP) for Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The performance period for these awards spanned three years from January 1, 2017, to December 31, 2019.
Key Financial Metrics and Performance Outcomes
The filing provides specific performance metrics used to determine vesting levels for the 2017 PSP, rather than general company financial statements. The outcomes were as follows:
- Adjusted Free Cash Flow: The Company achieved £13 billion over the three-year period, exceeding the £12.95 billion target required for maximum vesting (100% of this portion).
- R&D New Products: New Product sales reached £7.254 billion, surpassing the £5.099 billion target for maximum vesting (100% of this portion).
- Total Shareholder Return (TSR): GSK ranked 8th against a comparator group of 10 global pharmaceutical companies. This result fell below the threshold vesting level, resulting in 0% vesting for this portion.
Aggregate Vesting Result: Due to the TSR failure, 66.666% of the total award lapsed, while 33.334% vested.
Share Prices on Vesting Dates:
- Ordinary Shares: £16.616 (February 17, 2020)
- American Depositary Shares (ADSs): $43.55 (February 18, 2020)
Material Changes and Vesting Details
The primary material event is the partial vesting of equity awards on February 17 and 18, 2020. While the CEO's award vesting was extended to July 2020, awards for other Corporate Executive Team members vested immediately upon performance determination. The filing lists specific share volumes vested for various executives, including:
- Mr. L. Miels (President, Global Pharmaceuticals): 270,447 Ordinary Shares
- Mr. B. McNamara (CEO, GSK Consumer Healthcare): 64,736 ADSs
- Mr. R. Connor (President, Global Vaccines): 93,106 Ordinary Shares
- Mr. D. Redfern (Chief Strategy Officer): 66,645 Ordinary Shares
- Other executives received varying amounts of Ordinary Shares or ADSs, all at a transaction price of £0.00 or $0.00 as they were vesting events.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the inherent performance risks of the PSP. The document notes that adjustments to the original target and vesting schedule were previously communicated in the 2018 Annual Report. The primary contingency noted is the lapse of the TSR portion of the award due to underperformance relative to peers.
Key Facts for Investor Verification
- Verify the specific TSR ranking methodology and comparator group used to determine the 0% vesting on the shareholder return metric.
- Confirm the total number of shares issued to PDMRs versus the total number of shares that lapsed to assess the dilution impact.
- Review the 2018 Annual Report for details on the adjustments to the Adjusted Free Cash Flow target mentioned in this filing.
- Note that the CEO's vesting schedule differs from the rest of the executive team, with vesting delayed until July 2020.